Meet Proteona at the “LifeTime meets industry” conference in Basel, Switzerland
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Meet Proteona at the “LifeTime meets industry” conference, taking place on the 31st of October in Basel, Switzerland. The LifeTime Initiative aims to understand the underlying mechanisms of key diseases on a cellular and molecular level, so that doctors will be able to improve patient diagnosis and provide personalized treatment. It is built on key technologies including single cell analysis, artificial intelligence, and patient-derived organoids models.
Take the opportunity to meet with leading researchers and industry partners. Talk to us to find out how Proteona can contribute the LifeTime vision by applying single cell proteogenomics to solve clinical questions.
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a new biomedical company based in Singapore, Germany, and the US that is pioneering the use of DNA barcoded antibodies to provide both proteomic and genomic information from the same single cells. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research’s (A*STAR). The platform is a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles.